Intellectual Property Rights (IPR)

Exclusive marketing window granted to the first generic applicant(s) filing a Paragraph IV challenge against an Orange Book listed patent.

Quantitative determination of active content in dosage form using validated reversed-phase liquid chromatography. Applied specifically to Ciprofloxacin Hydrochloride.

Validated chromatographic assay quantifying active chemical potency (typically 98.0% – 102.0% for drug substance, 95.0% – 105.0% for finished dosage). Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

Validated chromatographic assay quantifying active chemical potency (typically 98.0% – 102.0% for drug substance, 95.0% – 105.0% for finished dosage). Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

Validated chromatographic assay quantifying active chemical potency (typically 98.0% – 102.0% for drug substance, 95.0% – 105.0% for finished dosage). Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

Kinetic turbidimetric or chromogenic LAL assay determining endotoxin concentration per mg or unit dose. Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

Kinetic turbidimetric or chromogenic LAL assay determining endotoxin concentration per mg or unit dose. Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

Kinetic turbidimetric or chromogenic LAL assay determining endotoxin concentration per mg or unit dose. Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

Statutory authorization granted by Controller of Patents allowing generic manufacturer to produce patented drug without patentee consent.

Individual chemical assay of 10 separate dosage units to confirm uniform active drug substance distribution. Applied specifically to Ciprofloxacin Hydrochloride.

Harmonized USP <905> uniformity evaluation assaying 10 to 30 individual dosage units. Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

Harmonized USP <905> uniformity evaluation assaying 10 to 30 individual dosage units. Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

Harmonized USP <905> uniformity evaluation assaying 10 to 30 individual dosage units. Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

Key manufacturing operating parameters (e.g. blend time, impeller RPM, compression force, drying temp) directly governing product CQAs. Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

Key manufacturing operating parameters (e.g. blend time, impeller RPM, compression force, drying temp) directly governing product CQAs. Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

Key manufacturing operating parameters (e.g. blend time, impeller RPM, compression force, drying temp) directly governing product CQAs. Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

In vitro drug release testing in compendial physiological media (pH 1.2, 4.5, 6.8) evaluated at multi-point intervals. Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

In vitro drug release testing in compendial physiological media (pH 1.2, 4.5, 6.8) evaluated at multi-point intervals. Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

In vitro drug release testing in compendial physiological media (pH 1.2, 4.5, 6.8) evaluated at multi-point intervals. Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

Multi-point in vitro release rate testing evaluated at 10, 15, 20, 30, 45, and 60 minutes in buffer. Applied specifically to Ciprofloxacin Hydrochloride.

Formal toxicological risk assessment under ICH Q3D evaluating potential Class 1, 2A, 2B, and 3 metal contamination via ICP-MS. Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

Formal toxicological risk assessment under ICH Q3D evaluating potential Class 1, 2A, 2B, and 3 metal contamination via ICP-MS. Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

Formal toxicological risk assessment under ICH Q3D evaluating potential Class 1, 2A, 2B, and 3 metal contamination via ICP-MS. Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

Authorized regulatory document compiling all required release tests (description, identity, assay, impurities, dissolution, microbial limits). Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

Authorized regulatory document compiling all required release tests (description, identity, assay, impurities, dissolution, microbial limits). Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

Authorized regulatory document compiling all required release tests (description, identity, assay, impurities, dissolution, microbial limits). Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

Mandatory annual declaration filed by patentees and licensees stating whether the patented invention is commercially manufactured in India.

Routine tests executed during manufacturing (tablet weight variation every 15 min, hardness, thickness, friability, DT every 30 min). Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

Routine tests executed during manufacturing (tablet weight variation every 15 min, hardness, thickness, friability, DT every 30 min). Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

Routine tests executed during manufacturing (tablet weight variation every 15 min, hardness, thickness, friability, DT every 30 min). Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

Five-year statutory exclusivity period granted to an innovative drug containing an active moiety never previously approved by the FDA.

FDA publication listing Approved Drug Products with Therapeutic Equivalence Evaluations and patent exclusivities.

Official USFDA publication listing approved prescription drugs, therapeutic equivalence evaluations (TE Codes like AB rating), reference listed drugs (RLDs), and patent/exclusivity data.

Official FDA publication (‘Approved Drug Products with Therapeutic Equivalence Evaluations’) listing all approved prescription drugs.

US regulatory incentive granted to medicines treating rare diseases affecting fewer than 200,000 Americans, providing tax credits, fee waivers, and 7 years of market exclusivity.

Certification by a generic applicant that an innovator patent listed in the Orange Book is invalid, unenforceable, or will not be infringed by generic manufacture.

Opposition filed by any interested party within one year after publication of the patent grant in the Patent Office Journal.

Legal mechanism allowing any person to file written opposition against a published patent application before patent grant.

Evaluation of barrier packaging (Alu-Alu vs PVC/PVDC vs HDPE bottles) protecting formulation against moisture, oxygen, and light. Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

Evaluation of barrier packaging (Alu-Alu vs PVC/PVDC vs HDPE bottles) protecting formulation against moisture, oxygen, and light. Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

Evaluation of barrier packaging (Alu-Alu vs PVC/PVDC vs HDPE bottles) protecting formulation against moisture, oxygen, and light. Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

Official FDA database listing licensed biological products, including reference products, biosimilars, and interchangeable biologics.

Gradient liquid chromatographic method resolving synthesis impurities and degradation products below ICH Q3A/B qualification thresholds. Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

Gradient liquid chromatographic method resolving synthesis impurities and degradation products below ICH Q3A/B qualification thresholds. Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

Gradient liquid chromatographic method resolving synthesis impurities and degradation products below ICH Q3A/B qualification thresholds. Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

Chromatographic separation and quantitation of synthesis intermediates and degradation impurities. Applied specifically to Ciprofloxacin Hydrochloride.

Headspace gas chromatography with flame ionization detection (HS-GC-FID) quantitating Class 1, 2, and 3 process solvents. Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

Headspace gas chromatography with flame ionization detection (HS-GC-FID) quantitating Class 1, 2, and 3 process solvents. Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

Headspace gas chromatography with flame ionization detection (HS-GC-FID) quantitating Class 1, 2, and 3 process solvents. Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

Famous anti-evergreening patent provision prohibiting patents on new forms, polymorphs, or salts of known substances unless efficacy is enhanced.

Evaluation of chemical, physical, and microbiological stability under accelerated environmental stress over 6 months. Applied specifically to Ciprofloxacin Hydrochloride.

Testing schedule (0, 3, 6, 9, 12, 18, 24, 36 months) evaluating long-term (25 deg C/60% RH) and accelerated (40 deg C/75% RH) chemical stability. Specific to Aripiprazole (Partial dopamine D2 and 5-HT1A receptor agonist antipsychotic).

Testing schedule (0, 3, 6, 9, 12, 18, 24, 36 months) evaluating long-term (25 deg C/60% RH) and accelerated (40 deg C/75% RH) chemical stability. Specific to Ciprofloxacin Hydrochloride (Broad-spectrum fluoroquinolone DNA gyrase inhibitor).

Testing schedule (0, 3, 6, 9, 12, 18, 24, 36 months) evaluating long-term (25 deg C/60% RH) and accelerated (40 deg C/75% RH) chemical stability. Specific to Ramipril (Prodrug ACE inhibitor converting to ramiprilat).

Codes assigned by FDA: ‘A’ codes indicate therapeutic equivalence (AB indicates bioequivalent); ‘B’ codes indicate actual or potential bioinequivalence.

Compendial dissolution apparatus moving outer reciprocating mesh cylinders through a series of flat-bottom glass outer tubes containing different dissolution media.